Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This is a new platform in non-myeloablative allogeneic stem cell transplantation to improve
survival by harnessing the immunologic potential of donor T-cells to induce and maintain
long-term remissions in patients with hematologic malignancies without undue toxicity. This
study involves is the first study in humans directed at optimizing the graft vs leukemia
effect by infusing activated T-cells from healthy donors prophylactically, months after
recovery from the initial transplant. Investigators are studying whether the activation of
donor cells prior to infusion will enhance the patient's ability to "seek and destroy"
residual malignant cells while also helping the immune system to fight infection without
increasing the immune reaction against the host.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania